GS1-144

Primary objective: To evaluate the efficacy of GS1-144 in the treatment of moderate to severe VMS; Secondary study objectives: 1) To evaluate the other efficacy of GS1-144 in the treatment of moderate to severe VMS; 2) To evaluate the safety and tolerability of GS1-144. Exploratory objectives: 1) To evaluate the population pharmacokinetic (PopPK) characteristics and exposure-effect analysis of GS1-144 and its metabolite M1; 2) To evaluate the improvement of sleep disturbance by GS1-144; 3) To evaluate the improvement of quality of life by GS1-144; 4) To evaluate the improvement of postmenopausal related symptoms by GS1-144; 5) To evaluate the effect of GS1-144 on pharmacodynamic (PD) markers (luteinizing hormone [LH]); 6) To evaluate the effect of GS1-144 tablets on sex hormones (excluding LH) and sex hormone binding globulin; 7) To evaluate the effect of GS1-144 tablets on bone metabolism.